Method for separation and purification of naltrexone by preparative chromatography
View Patent ↗A process for the purification of an impure preparation containing naltrexone by means of a reverse phase preparative chromatography process is provided. In an illustrative embodiment a chromatographic column is loaded with a stationary phase, typically a silica particle having an organic ligand bound thereto. With a loading ratio of from about 10 to about 1000 the impure preparation is acidified and passed through the column. The column is eluted with typically an aqueous solution with acetonitrile and the purified naltrexone is obtained in a specified fraction.
1. A process for recovering highly pure naltrexone from an impure naltrexone preparation, the process comprising:
loading the impure naltrexone preparation into a reverse-phase preparative chromatographic column, wherein the loading ratio of a stationary phase to naltrexone is not more than about 1000; and
recovering highly pure naltrexone by eluting the naltrexone from the reverse-phase preparative chromatographic column with a mobile phase, wherein the highly pure naltrexone recovered is at least about 95% pure.
2. The process of claim 1 wherein the loading ratio is in the range of about 10 to about 1000.
3. The process of claim 1 wherein the loading ratio is in the range of about 20 to about 40.
4. The process of claim 1 wherein the stationary phase is selected from the group consisting of alkylsilanes, arylsilanes, haloalkylsilanes, alkyl esters, aryl esters, alkyl amines, alkylcyano compounds, alkyldiols, alkyl ethers, aryl ethers, haloalkyl ethers, alkylcarboxylic acids, arylcarboxylic acids, alkysulfonic acids, arylsulfonic acids, polystyrenedivinylbenzene, aminopolycaprolactem, glycidoxyethylmethoxysilzne and mixtures thereof.
5. The process of claim 1 wherein the stationary phase is a bonded-phase silica containing ligands selected from the group consisting of butyl-, octyl-, octadecyl-, tricosane-, cyano- and phenyl-moieties, and mixtures thereof.
6. The process of claim 5 wherein the ligand is octadecyl-silane.
7. The process of claim 1 wherein the mobile phase comprises water, acid and an organic solvent.
8. The process of claim 7 wherein the acid in the mobile phase is selected from the group consisting of acetic acid, malic acid, tartaric acid, sulfuric acid, formic acid, oxalic acid, lactic acid, hydrochloric acid, hydrobromic acid, phosphoric acid, phosphorous acid, nitric acid and mixtures thereof.
9. The process of claim 8 wherein the pH of the mobile phase is about 1 to about 7.
10. The process of claim 9 wherein the pH of the mobile phase is about 3.5 to about 5.5.
11. The process of claim 7 wherein the organic solvent includes at least one alcohol.
12. The process of claim 11 wherein the at least one alcohol is selected from the group consisting of methanol, propanol, isopropanol, butanol, butanol and mixtures thereof.
13. The process of claim 7 wherein the organic solvent includes acetonitrile.
14. The process of claim 13 wherein the acetonitrile is about 5 to about 100 volume percent.
15. The process of claim 13 where the acetonitrile is up to 10 volume percent during the recovery of the purified naltrexone.
16. The process of claim 1 further comprising acidifying the impure naltrexone preparation to form a naltrexone salt prior to subjecting the impure naltrexone preparation to reverse-phase liquid chromatography.
17. The process of claim 16 wherein the impure naltrexone preparation is acidified with at least one inorganic acid.
18. The process of claim 17 wherein the at least one inorganic acid is selected from the group consisting of sulfuric acid, hydrochloric acid, hydrobromic acid, phosphoric acid, phosphorous acid, nitric acid and mixtures thereof.
19. The process of claim 16 wherein the impure naltrexone preparation is acidified with at least one organic acid.
20. The process of claim 19 wherein the organic acid is selected from the group consisting of acetic acid, malic acid, tartaric acid, formic acid, oxalic acid, lactic acid and mixtures thereof.
21. The process of claim 16 wherein the pH of the impure naltrexone preparation is about 1 to about 7.
22. The process of claim 21 wherein the pH of the impure naltrexone preparation is about 2 to about 3.
23. A process for purifying an impure naltrexone preparation containing 2,2-bisnaltrexone and N-(3-butenyl)noroxymorphone, the process comprising the steps of
(a) packing a preparative chromatographic column with a chromatographic packing material;
(b) passing through the packed, preparative chromatographic column an aqueous, acidified solution of naltrexone preparation at a loading ratio of from about 10 to about 1000; and
(c) eluting naltrexone from the packed chromatographic column with a mobile phase comprising water and an organic solvent to produce an eluate containing a purified naltrexone with less than 0.50 area % 2,2-bisnaltrexone and less than 0.50 area % N-(3-butenyl)noroxymorphone.
24. The process of claim 23 further including dividing the eluate into at least four fractions wherein:
(i.) a first fraction is discarded,
(ii.) a second fraction is combined with a fourth fraction wherein the water and organic solvent are substantially reduced and then recycled through the column, and
(iii.) a third fraction that contains less than 0.50 area % 2,2-bisnaltrexone and N-(3-butenyl)noroxymorphone is recovered.